JP4393064B2 - How to use tyramine as a cosmetic ingredient to make white skin - Google Patents
How to use tyramine as a cosmetic ingredient to make white skin Download PDFInfo
- Publication number
- JP4393064B2 JP4393064B2 JP2002520780A JP2002520780A JP4393064B2 JP 4393064 B2 JP4393064 B2 JP 4393064B2 JP 2002520780 A JP2002520780 A JP 2002520780A JP 2002520780 A JP2002520780 A JP 2002520780A JP 4393064 B2 JP4393064 B2 JP 4393064B2
- Authority
- JP
- Japan
- Prior art keywords
- tyramine
- cosmetic composition
- whitening cosmetic
- composition according
- whitening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 title claims description 58
- 229960003732 tyramine Drugs 0.000 title claims description 58
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 title claims description 58
- 239000008406 cosmetic ingredient Substances 0.000 title description 2
- 239000002537 cosmetic Substances 0.000 claims description 22
- 230000002087 whitening effect Effects 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 241001672694 Citrus reticulata Species 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 210000004209 hair Anatomy 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- -1 macroparticles Substances 0.000 claims description 5
- 239000000516 sunscreening agent Substances 0.000 claims description 4
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000002088 nanocapsule Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 230000019612 pigmentation Effects 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 241000555678 Citrus unshiu Species 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000003581 cosmetic carrier Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 31
- 230000000694 effects Effects 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 8
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000049 pigment Substances 0.000 description 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000003241 dermatological agent Substances 0.000 description 4
- 229940000033 dermatological agent Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000012015 potatoes Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101150002885 Avil gene Proteins 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 241000605411 Lloydia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000021383 camembert cheese Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- IGGVVGHJSQSLFO-UHFFFAOYSA-N indole-5,6-quinone Chemical compound O=C1C(=O)C=C2C=CNC2=C1 IGGVVGHJSQSLFO-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M23/00—Treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, characterised by the process
- D06M23/12—Processes in which the treating agent is incorporated in microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/415—Aminophenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
- D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
- D06M13/368—Hydroxyalkylamines; Derivatives thereof, e.g. Kritchevsky bases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/002—Aftershave preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q9/00—Preparations for removing hair or for aiding hair removal
- A61Q9/04—Depilatories
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Textile Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【０００１】
表皮の特殊細胞で合成されるメラニンは色素細胞でこれによって皮膚の色が与えられる。普通の肌では、メラニンの合成は種々のファクターによって調整されている。このファクターの中でも良く知られているのが太陽光線で、メラニンは照射される紫外線（ＵＶ）（通常の生活での日光露出や自然の太陽光線照射、又はビューティーサロンのＵＶ照射等）の線量に比例して増加する。これは日焼けとして現われる。比較的軽い或いは生理上の障害としてのメラニンが発生すると、そばかす、ほくろ、広がったしみ（クロアスマ、妊娠シミ）として現われる。老化による自然な生理的障害は多数あるが、そのうちメラニン色素の発生としては不規則に発現する老化性シミがある。
【０００２】
生命に直接関わるのでない種々の不都合を調整するため、化粧品産業が独自の解決法を提供するのは、その当然の役割を果たしているといえる。
肌の色素過剰を手当てするため、多種の化学分子や物質が提供されてきた。しかし、そのうちで化粧品への適用として採用されたものは非常に少ない（かぶれ、法規上の規制、有毒性の問題などがあるため。）。そして、この選択に残ったものはあまり効果的でないのが一般的である。
化粧品又は皮膚薬品の成分としてチラミンを使用することが、この問題に有効な解答を与えることが明らかにされたので、本発明を特許として出願することにした。
【０００３】
主として食物の中に存在する（生チーズ、キャベツ、じゃがいも、鰯、グルイエールチーズ、キアンティ、カマンベールチーズ等）チラミンは、今日まで製薬や化粧品には殆ど使用されていない。チラミンは調剤や診断において使用される（ＥＰ０７９５６１０）、或いは鬱症の治療（ＵＳ４８６８２１８）、及び／又はアルツハイマー病やパーキンソン病（ＥＰ０４０６４８８）の治療、又はコレステロール生成防止（ＵＳ４８５７５２２）剤として使用されてきた。
【０００４】
生化学上の説明では、チラミンはドーパミンの直接前駆体である。ドーパに近い化学構造であるから、チラミンは抗チロシナーゼ効果を有するのではないか、そしてこれによって上記状況でおこるメラニン色素の生成を減少させるような製品が可能であろうという仮定を立てた。
【０００５】
ところで、メラニン細胞は、チロシンがメラニンに変化するときの触媒酵素であるチロシナーゼとＯ−ジフェノールオキシダーゼを含んでいる。その反応は、以下の式で表される。
チロシン⇒ドーパ⇒ドーパキノン⇒ドーパクロム⇒インドールキノン⇒メラニン
【０００６】
アルビノ（色素欠乏症）のヒトは、先天的にＯ−ジフェノールオキシダーゼが欠乏しており、これによってメラニン形成ができず、従って皮膚色素が欠如しているわけである。
【０００７】
本発明の目的は、チラミンがそれ自身はドーパに変化することなく、システムを阻害することによって、メラニン形成を減少するように作用するということを証明するものである。すなわち、メラニンは代替物質ではなく競争阻害物質である。
【０００８】
チラミンは様々な素材料から得ることができる。チラミンを含有する植物は全て原料として利用することができるが、その中でも特に、マンダリン（Citrus reticulata）はチラミンを豊富に含んでいる（Wheaton TA ＆ Stewart I(1970) Lloydia 33：244-254）ので、植物体全体または一部から抽出によってチラミンを得ることができる。
【０００９】
植物全体又はその一部（１５ｇ）を８５ｇの蒸留水に浸漬し、常温で４８時間スクリュー攪拌する。植物は分散して水の体積と同量になる。濾過（８００μｍ）後、抽出液はそのまま使用することができる。
或いは、後述する形態に利用できるように、従来の物質乾燥方法によって乾燥抽出体にすることもできる。
【００１０】
高速液体クロマトグラフィーによる分析によって、このようにして得られた抽出体はチラミンを含んでいることが示される。植物の原産地や収穫時期によってチラミン含有量が異なることがあるが、この分野の専門家であればチラミン含有量が一定になるように抽出体を調整することができる。
【００１１】
マンダリン（Citrus reticulata）抽出からチラミンを収集する方法は、上述のものに限定されない。例えば、浸漬、煎じ法、浸出、還流、超音波やマイクロ波による抽出、洗浄法等の方法でエキス抽出が可能である。方法は例示したものに限定されない。
また抽出溶剤としては、上記のものに限定されず、水、プロピレングリコール、ブチレングリコール、グリセリン、ポリエチレングリコール、メチルエーテルジグリコール、エチルエーテルジグリコール、環状ポリアルコール、エトキシルジグリコール、プロポキシルジグリコール、アルコール（メタノール、エタノール、プロパノール、ブタノール）、またはこれらの混合溶媒を使用することができる。
【００１２】
本発明において期待される活性を得るためのチラミンは、以下のように要約される。
・植物の抽出エキスから得られ、例えば陳皮（Citrus unshiu Mare.）、好ましくはマンダリン（Citrus reticulata）から抽出されるものが好ましい。
・あらゆる方法の化学合成からも得られる。
・単独または他の活性分子と組み合わせて使用することができる。
・精製され、リポゾーム等のサポート媒体に付けられる。
・１乃至２４個の炭素原子を含む、直鎖または分岐の、飽和化合物又は不飽和化合物の、或いはヒドロキシル基化合物又はイオウ化合物を含むか含まない、アルキル基分子鎖によって、ＯＨ基又はＮＨ２基に接合したもの。
【００１３】
チラミンは化粧品や皮膚用薬品に使用される植物成分の含有形態として配合される。例えば、以下に二つの成分構成を例示する。
【００１４】
例１ 日常クリーム
ボルポＳ２０ ２．４ｇ
ボルポＳ２ ２．６ｇ
プロステアリル１５ ８．０ｇ
ミツロウ ０．５ｇ
アビル（登録商標）ＺＰ２４３４ ３．０ｇ
プロピレングリコール ３．０ｇ
カーボポール（登録商標）１９４１ ０．２５ｇ
トリエタノールアミン ０．２５ｇ
チラミン ５．０ｇ
水分及び防腐剤を加えて１００ｇとする。
【００１５】
例２ ボディーローション美白デオドラント
クリレット３ ２．５ｇ
ノボル ０．９ｇ
フルイラン ２．５ｇ
カーボポール９４０ ０．３ｇ
ミツロウ ２．０ｇ
トリエタノールアミン ０．１ｇ
グリセリン ５．０ｇ
チラミン ３．０ｇ
水分及び防腐剤を加えて１００ｇとする。
【００１６】
以下の例において、チラミンの美白作用効果を証明する。
例３ ヒトチロシナーゼ阻害作用（インビトロ試験）
この例ではドーパミンオキシダーゼの活性が明らかにされる。培養されたヒト正常メラニン細胞（ＭＮＨ）をイゲパル緩衝液と超音波で溶解させ、この抽出細胞をそれぞれ重量濃度０．１％、０．３％、１％のチラミンを含む緩衝液およびチラミンを含まないコントロール液に接触させた。
チロシナーゼの活性度は、Ｌ−ドーパオキシダーゼ活性から、Ｌ−ドーパからつくられたドーパクロムの量を波長４９０ｎｍにおける光学スペクトル濃度測定によって定量化した。反応はＬ−ドーパを加えることにより開始された。
波長４９０ｎｍで、開始より１時間後までは１０分ごとに、２時間後までは３０分ごとに動的変化を追跡した。異なる緩衝液における８回のテスト結果をコントロール液と比較した。阻害作用の平均結果をパーセント表示で以下の表１に記載する。
【００１７】
【表１】
この表１の結果によれば、チラミンの存在でチロシナーゼ活性が非常に低下することが示されている。チラミンの存在、非存在がこの実験の唯一の変数であるから、観察された効果はチラミンに由来するものであることは明らかである。また観察されたこのシステムの効果は、明らかに濃度依存性を示しているから、チラミンに特徴付けられる効果といえる。
またこの実験はＬ−ドーパおよびチラミンなしのテストを行い、システムの安定性が確認されている。
【００１９】
例４ チロシナーゼの阻害作用（インビトロ実験）
生理的効果を立証するため、ヒト細胞を使用することは理にかなっているが、試料提供者の個人差があるので、時として結果が対象ごとに大差を示すことは周知の事実である。
この理由から、前記のテスト結果は、チラミンのチロシナーゼに対する阻害効果を疑いなく示すものであるが、他のモデルを使用して別の実験を行った。
この例で用いた細胞は、メラニンを多数生成し、チロシナーゼ活性やメラニン合成の活性に関する研究に広く使用されているメラノーマＢ１６細胞である。
この細胞を培養プレートのくぼみ（１プレートにつき２４個のくぼみが設けてある）に植えつけ、３７℃で２４時間培養した。洗浄後、細胞はチラミン濃度がそれぞれ０．０１％、０．０３％の緩衝液、またチラミンを含まないコントロール液に４８時間接触させた。
比較例として、濃度０．０１×１０−２％のハイドロキノン液を用いた。前記実験と同様、細胞はイゲパル緩衝液で超音波を用い溶解して測定した。活性チロシナーゼ量は共存するタンパク質量当りに換算することで標準化した。
【００２０】
【表２】
この結果は、チラミン存在のためチロシナーゼ活性が非常に減少していること、それは相当する濃度のハイドロキノンによるものより良い効果を示している。チラミンの存在、非存在がこの実験の唯一の変数であるから、観察された効果はチラミン由来のものであることは明らかである。また実験は二種類の異なる濃度のチラミンで行われたに過ぎないが、観察されたこのシステムの効果は明らかに濃度依存性を示し、チラミンに特徴付けられる効果といえる。
【００２２】
例５．合成チラミンの阻害作用（インビトロ試験）
培養（６０％と８０％の混合）されたヒト正常メラニン細胞（ＭＮＨ）を、それぞれチラミン濃度が０．００３％と０．０１％の緩衝液、およびチラミンを含まないコントロール液中で接触させた。８日間緩衝液と接触させ、この期間中、細胞を維持するため毎日同じ濃度（重量濃度で０．００３％と０．０１％）の緩衝液を更新した。
この期間中、半数のプレートを五回にわたって紫外線ＵＶ−Ｂ（２０ｍＪ／ｃｍ２）で照射した。他の半数のプレートは照射しなかった。
８日後、細胞を培養から取り出し洗浄した。抽出後、細胞間メラニンの量を従来の光学スペクトル濃度測定法で測定した。この測定値は、一定細胞数当りに換算して標準化した。
【００２３】
以下に、実験後の平均阻害効果率パーセンテージ（５回の異なるテストの）結果を、同じ時間で実験した比較例と比較して示す。
【表３】
この結果は、
・一方、ＵＶ−Ｂ照射がない場合、チラミン量に基づいたメラニンの減少効果が示されている。すなわち形成されるメラニンの全体量が減少されるから期待される美白効果となる。
・他方、ＵＶ−Ｂを五回照射した後も、チラミンの存在でメラニン生成の阻害効果は維持され、比較例より低い値を示している。このように、紫外線照射による新しいメラニンの合成促進効果（比較例でほぼ２倍）は限定される。
【００２５】
チラミンの存在、非存在がこの実験の唯一の変数であるから、観察された効果はチラミン由来のものであることは明らかである。また実験は二つの違う濃度のチラミンでしか行われていないが、観察されたこのシステムの効果は、明らかに濃度依存性を示しているから、チラミンに特徴付けられる効果であるといえる。
【００２６】
例６．抗シミ作用（臨床試験）
この実験は、年齢が４５歳から６５歳で、肌や手に老化性シミのある女性志願者を対象に行った。
被験者の一方の手の五ケ所のシミを選び、色と大きさを正確に測定した後、例１に記述したテスト物質（５％）含有クリームを１．５ヶ月間にわたって一方の手（どちらでもよい）にだけ塗り、他方の手は比較例として、テスト物質を含まないクリームを塗った。結果を標準化するため、当然、シミの無い皮膚５箇所の色素測定も行った。１ヶ月後、および１．５ヶ月後に皮膚の色素定量化を行った。メラニン色素の量はメキサ測定器で測定した。この機器はセンサー中に内蔵された異なる三色光を発する特殊ランプでメラニン量を測るものである。
テスト物質を塗った手の老化性シミの色は、チラミンを含まないクリームで処理した手に比較して、一ヶ月で６．４％、１．５ヶ月後で２４％低くなった。
この実験は２０００年春、特に太陽光の多い時期に行われたことを考慮すると、結果の著しい効果を示しているといえる。
【００２７】
これらの例はいずれも美白効果および自然光または人工のUV照射による皮膚の着色を弱める効果をはっきりと証明している。
最終の化粧品または皮膚用薬品成分として、チラミンの重量濃度は０．００１〜１０％の範囲で、好ましくは０．０１〜７．０％がよい。
チラミンは化粧品や皮膚用薬品で使用されるあらゆる形態で使用することができる。すなわち、Ｏ／Ｗ又はＷ／Ｏエマルション、乳液、ローション、ポマード、ヘアローション、シャンプー、石鹸、スティック、ペンシル、スプレー、ボディオイルなどの形態で、使用することができる。但し、これらの形態に限定されるものではない。
【００２８】
チラミンを化粧品用のキャリアに取り込むことも可能である。例えば、リポゾーム、マイクロエマルション、マクロ粒子、ミクロ粒子、ナノ粒子、あるいはマクロカプセル、ミクロカプセル、ナノカプセルなどの媒体に取り込んだり、粉状有機ポリマーやタルク、ベントナイト等の鉱物サポートに吸収させたりすることもできる。
チラミンは通常化粧品で使用されるその他のいかなる材料とも組み合わせて化粧品成分とすることができる。例えば、天然抽出または合成の脂質、ゲル状および粘質のポリマー、界面活性剤およびエマルション、水溶性活性剤または脂溶性活性剤、他の植物からの抽出物、繊維抽出物、海産物抽出物などを例示することができる。
【００２９】
チラミンを含む化粧品または皮膚用薬品としてはクリーム、芳香剤、ゲル、ローション状、またはクリーム状の日焼け止めや日焼け止め処置薬、アフターシェービング、脱毛剤、脱毛後手入れクリームなどがある。
チラミンは、肌の手入れ、特に肌を色白にしたり、人工または自然の紫外線照射時の色素沈着を軽減するあらゆる化粧品または皮膚用薬品の中に混入したりすることができる。
化粧品または皮膚用薬品のこれらの成分は、肌の手入れ、特に肌を白くしたり、人工または自然の紫外線照射時の色素沈着を軽減したりするための薬品下地に使用される。
【００３０】
チラミンは化粧品または皮膚用薬品の中に単体または複合体として使用され、マクロ、ミクロ、ナノ粒子やマクロ、ミクロ、ナノカプセルのかたちで化学結合、混入、吸収、吸着させ、織物、天然または合成の繊維、羊毛など昼夜を問わず肌や毛髪と直接接触することによって局所的にチラミンを連続放出するような着物や下着を仕立てるものに用いるあらゆる材料の中に使用される。[0001]
Melanin synthesized in special cells of the epidermis is a pigment cell, which gives the skin color. In normal skin, melanin synthesis is regulated by various factors. Of these factors, sunlight is well known, and melanin is the dose of ultraviolet rays (UV) that are irradiated (sunlight exposure in normal life, natural sunlight irradiation, or beauty salon UV irradiation, etc.). Increase proportionally. This appears as a tan. When melanin occurs as a relatively mild or physiological disorder, it appears as freckles, moles, spread stains (cloasma, pregnancy spots). There are many natural physiological disorders due to aging. Among them, there are aging spots that appear irregularly as melanin development.
[0002]
It can be said that the cosmetic industry plays its own role in order to adjust various inconveniences not directly related to life.
A variety of chemical molecules and substances have been provided to treat excess skin pigment. However, very few of them have been adopted for cosmetic applications (because of rashes, regulatory restrictions, toxicity issues, etc.). And what remains of this choice is generally not very effective.
Since the use of tyramine as a cosmetic or dermatological ingredient has been shown to provide an effective answer to this problem, the present invention was filed as a patent.
[0003]
Tyramine, which is mainly present in food (raw cheese, cabbage, potatoes, potatoes, gruyere cheese, chianti, camembert cheese, etc.) is rarely used in pharmaceuticals and cosmetics to date. Tyramine has been used in formulation and diagnosis (EP 07956610), or treatment of depression (US 4868218), and / or treatment of Alzheimer's disease or Parkinson's disease (EP 0406488), or cholesterol production prevention (US 4857522).
[0004]
In the biochemical description, tyramine is a direct precursor of dopamine. Since it has a chemical structure close to that of dopa, it was hypothesized that tyramine would have an anti-tyrosinase effect and that this would enable a product that would reduce the production of melanin pigments occurring in the above situation.
[0005]
By the way, melanocytes contain tyrosinase and O-diphenol oxidase which are catalytic enzymes when tyrosine changes to melanin. The reaction is represented by the following formula.
Tyrosine ⇒ Dopa ⇒ Dopaquinone ⇒ Dopachrome ⇒ Indolequinone ⇒ Melanin [0006]
Humans with albino (pigment deficiency) are congenitally deficient in O-diphenol oxidase, thereby failing to form melanin and thus lacking skin pigment.
[0007]
The purpose of the present invention is to prove that tyramine acts to reduce melanogenesis by inhibiting the system without itself changing to dopa. That is, melanin is not a substitute but a competitive inhibitor.
[0008]
Tyramine can be obtained from a variety of raw materials. All plants containing tyramine can be used as raw materials, but mandarin (Citrus reticulata) is particularly rich in tyramine (Wheaton TA & Stewart I (1970) Lloydia 33: 244-254). Tyramine can be obtained by extraction from all or part of the plant body.
[0009]
The whole plant or a part thereof (15 g) is immersed in 85 g of distilled water, and is stirred with a screw at room temperature for 48 hours. Plants disperse to the same volume as water. After filtration (800 μm), the extract can be used as it is.
Or it can also be made into a dry extract by the conventional substance drying method so that it can utilize for the form mentioned later.
[0010]
Analysis by high performance liquid chromatography shows that the extract thus obtained contains tyramine. The tyramine content may vary depending on the plant's origin and harvest time, but an expert in this field can adjust the extract so that the tyramine content is constant.
[0011]
The method of collecting tyramine from mandarin (Citrus reticulata) extraction is not limited to the one described above. For example, the extract can be extracted by a method such as dipping, decoction, leaching, reflux, extraction with ultrasonic waves or microwaves, or a washing method. The method is not limited to that illustrated.
Further, the extraction solvent is not limited to the above, but water, propylene glycol, butylene glycol, glycerin, polyethylene glycol, methyl ether diglycol, ethyl ether diglycol, cyclic polyalcohol, ethoxyl diglycol, propoxyl diglycol, alcohol (Methanol, ethanol, propanol, butanol) or a mixed solvent thereof can be used.
[0012]
Tyramine for obtaining the activity expected in the present invention is summarized as follows.
-It is obtained from an extract of a plant, for example, one extracted from citrus unshiu Mare., Preferably mandarin (Citrus reticulata).
• Can be obtained from any method of chemical synthesis.
Can be used alone or in combination with other active molecules.
・ Purified and attached to a support medium such as liposome.
· Containing 1 to 24 carbon atoms, linear or branched, saturated or unsaturated compounds, or with or without hydroxyl groups or sulfur compounds, depending on the alkyl group molecular chain, OH groups or NH 2 groups What was joined to.
[0013]
Tyramine is blended as a plant component used in cosmetics and dermatological agents. For example, two component structures are illustrated below.
[0014]
Example 1 Daily cream Volpo S20 2.4g
Volpo S2 2.6g
Prostearyl 15 8.0g
Beeswax 0.5g
Avil (registered trademark) ZP2434 3.0 g
Propylene glycol 3.0g
Carbopol (registered trademark) 1941 0.25g
0.25 g of triethanolamine
Tyramine 5.0g
Add water and preservatives to 100 g.
[0015]
Example 2 Body Lotion Whitening Deodorant Krillet 3 2.5g
Noboru 0.9g
Fluilan 2.5g
Carbopol 940 0.3g
Beeswax 2.0g
Triethanolamine 0.1g
Glycerin 5.0g
Tyramine 3.0g
Add water and preservatives to 100 g.
[0016]
The following example demonstrates the whitening effect of tyramine.
Example 3 Human tyrosinase inhibitory action (in vitro test)
In this example, the activity of dopamine oxidase is revealed. Cultured human normal melanocytes (MNH) are lysed with Igepal buffer and ultrasound, and the extracted cells contain buffer solution containing tyramine at a weight concentration of 0.1%, 0.3% and 1% and tyramine, respectively. No contact with control solution.
The activity of tyrosinase was quantified from the L-dopa oxidase activity by measuring the amount of dopachrome produced from L-dopa by optical spectral densitometry at a wavelength of 490 nm. The reaction was started by adding L-dopa.
Dynamic changes were followed at a wavelength of 490 nm every 10 minutes up to 1 hour after the start and every 30 minutes up to 2 hours. Eight test results in different buffers were compared with the control solution. The average results of the inhibitory action are listed in Table 1 below as a percentage.
[0017]
[Table 1]
The results in Table 1 indicate that tyrosinase activity is greatly reduced in the presence of tyramine. Since the presence or absence of tyramine is the only variable in this experiment, it is clear that the observed effect is derived from tyramine. In addition, the observed effect of this system clearly shows concentration dependence, and can be said to be an effect characterized by tyramine.
The experiment was also tested without L-dopa and tyramine, confirming the stability of the system.
[0019]
Example 4 Inhibitory action of tyrosinase (in vitro experiment)
Although it makes sense to use human cells to demonstrate physiological effects, it is a well-known fact that the results sometimes vary greatly from subject to subject due to individual differences among sample providers.
For this reason, the test results clearly show the inhibitory effect of tyramine on tyrosinase, but other experiments were performed using other models.
The cells used in this example are melanoma B16 cells that produce many melanins and are widely used for research on tyrosinase activity and melanin synthesis activity.
The cells were inoculated into the wells of the culture plate (24 wells were provided per plate) and cultured at 37 ° C. for 24 hours. After washing, the cells were contacted with a buffer solution having a tyramine concentration of 0.01% and 0.03%, respectively, and a control solution not containing tyramine for 48 hours.
As a comparative example, a hydroquinone liquid having a concentration of 0.01 × 10 −2 % was used. As in the previous experiment, cells were measured by lysis using ultrasound with Igepal buffer. The amount of active tyrosinase was standardized by converting to the amount of coexisting protein.
[0020]
[Table 2]
This result shows that tyrosinase activity is greatly reduced due to the presence of tyramine, which is a better effect than with the corresponding concentration of hydroquinone. Since the presence or absence of tyramine is the only variable in this experiment, it is clear that the observed effect is from tyramine. The experiment was only conducted with two different concentrations of tyramine, but the observed effects of this system are clearly concentration-dependent and can be characterized as tyramine.
[0022]
Example 5. Inhibitory action of synthetic tyramine (in vitro test)
Cultured (60% and 80% mixed) human normal melanocytes (MNH) were contacted in buffers with tyramine concentrations of 0.003% and 0.01%, respectively, and a control solution without tyramine. . The buffer was renewed at the same concentration (0.003% and 0.01% by weight) daily to maintain the cells during this period in contact with the buffer for 8 days.
During this period, half of the plates were irradiated five times with UV-B (20 mJ / cm 2 ). The other half of the plates were not irradiated.
After 8 days, the cells were removed from the culture and washed. After extraction, the amount of intercellular melanin was measured by a conventional optical spectral densitometry method. This measured value was standardized by converting per fixed number of cells.
[0023]
Below, the mean percentage inhibition rate after experiment (from 5 different tests) results are shown in comparison with the comparative examples run at the same time.
[Table 3]
The result is
-On the other hand, when there is no UV-B irradiation, the reduction effect of melanin based on the amount of tyramine is shown. That is, the whitening effect is expected because the total amount of melanin formed is reduced.
-On the other hand, even after UV-B was irradiated five times, the inhibitory effect of melanin production was maintained in the presence of tyramine, indicating a lower value than in the comparative example. Thus, the effect of promoting the synthesis of new melanin by ultraviolet irradiation (approximately twice in the comparative example) is limited.
[0025]
Since the presence or absence of tyramine is the only variable in this experiment, it is clear that the observed effect is from tyramine. The experiment was only conducted at two different concentrations of tyramine, but the observed effects of this system are clearly concentration-dependent and can be said to be characterized by tyramine.
[0026]
Example 6 Anti-staining effect (clinical trial)
This experiment was conducted on female volunteers aged 45 to 65 who have aging spots on their skin and hands.
After five spots on one hand of the subject were selected and the color and size were accurately measured, the cream containing the test substance (5%) described in Example 1 was applied to one hand (either The other hand was applied with a cream containing no test substance as a comparative example. In order to standardize the results, naturally, pigment measurement was also performed on five spots without skin spots. Skin pigment quantification was performed after 1 month and 1.5 months. The amount of melanin pigment was measured with a mexa meter. This device measures the amount of melanin with a special lamp that emits three different colors of light built into the sensor.
The color of the aging spots on the hands coated with the test substance was 6.4% lower in one month and 24% lower after 1.5 months compared to hands treated with cream without tyramine.
Considering that this experiment was carried out in the spring of 2000, especially during the day when there was a lot of sunlight, it can be said that the result shows a remarkable effect.
[0027]
Both of these examples clearly demonstrate a whitening effect and an effect that attenuates skin coloration by natural light or artificial UV irradiation.
As a final cosmetic or dermatological chemical component, the weight concentration of tyramine is in the range of 0.001 to 10%, preferably 0.01 to 7.0%.
Tyramine can be used in any form used in cosmetics and dermatological agents. That is, it can be used in the form of O / W or W / O emulsion, emulsion, lotion, pomade, hair lotion, shampoo, soap, stick, pencil, spray, body oil and the like. However, it is not limited to these forms.
[0028]
It is also possible to incorporate tyramine into a cosmetic carrier. For example, it can be taken into a liposome, microemulsion, macroparticle, microparticle, nanoparticle, or a medium such as macrocapsule, microcapsule, nanocapsule, or absorbed into a mineral support such as powdered organic polymer, talc, or bentonite. You can also.
Tyramine can be combined with any other material normally used in cosmetics to make a cosmetic ingredient. For example, natural or synthetic lipids, gel-like and viscous polymers, surfactants and emulsions, water-soluble or fat-soluble active agents, extracts from other plants, fiber extracts, marine product extracts, etc. It can be illustrated.
[0029]
Cosmetic or dermatological agents containing tyramine include creams, fragrances, gels, lotions, or creamy sunscreens and sunscreens, aftershaves, hair removers, post-hair removal care creams, and the like.
Tyramine can be incorporated into any cosmetic or dermatological agent that cares for the skin, in particular the skin becomes pale, or reduces pigmentation during artificial or natural UV irradiation.
These components of cosmetic or dermatological chemicals are used in drug bases for skin care, in particular for whitening the skin and reducing pigmentation during artificial or natural UV irradiation.
[0030]
Tyramine is used as a simple substance or complex in cosmetics or dermatological chemicals, chemically bonded, mixed, absorbed, adsorbed in the form of macro, micro, nano particles or macro, micro, nano capsules, textile, natural or synthetic It is used in all materials used for making kimonos and underwear that continuously release tyramine locally by direct contact with skin and hair, such as fiber and wool.
Claims (8)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0011002A FR2813188B1 (en) | 2000-08-25 | 2000-08-25 | USE OF TYRAMINE IN COSMETIC COMPOSITIONS FOR CLEARING THE SKIN |
| PCT/FR2001/002597 WO2002015871A1 (en) | 2000-08-25 | 2001-08-10 | Use of tyramine in cosmetic compositions to lighten the skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004506677A JP2004506677A (en) | 2004-03-04 |
| JP4393064B2 true JP4393064B2 (en) | 2010-01-06 |
Family
ID=8853770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002520780A Expired - Lifetime JP4393064B2 (en) | 2000-08-25 | 2001-08-10 | How to use tyramine as a cosmetic ingredient to make white skin |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP4393064B2 (en) |
| AU (1) | AU2001284135A1 (en) |
| FR (1) | FR2813188B1 (en) |
| WO (1) | WO2002015871A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841550B1 (en) * | 2002-06-26 | 2007-05-04 | Sederma Sa | NOVEL MOLECULES DERIVED FROM TYRAMINE, THEIR METHOD OF PREPARATION, AND THEIR USE ONLY OR ASSOCIATED IN COSMETIC OR DERMOPHARMEUTICAL COMPOSITIONS |
| EP1686957B1 (en) | 2003-11-17 | 2012-03-07 | Sederma | Compositions containing mixtures of tetrapeptides and tripeptides |
| FR2890310B1 (en) | 2005-09-06 | 2009-04-03 | Sederma Soc Par Actions Simpli | USE OF PROTOBERBERINS AS AGENTS REGULATING THE ACTIVITY OF THE PILOSEBACEE UNIT |
| JP2007106697A (en) * | 2005-10-13 | 2007-04-26 | Sederma Sa | New tyramine derivative, method for production of the same, cosmetic composition including the derivative or medicinal composition for skin |
| ES2638242T3 (en) | 2006-02-16 | 2017-10-19 | Sederma | KXK polypeptides and their use |
| FR2900573B1 (en) | 2006-05-05 | 2014-05-16 | Sederma Sa | NOVEL COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE PEPTIDE CONTAINING AT LEAST ONE BLOCKED AROMATIC CYCLE |
| JP4960948B2 (en) * | 2008-10-31 | 2012-06-27 | 共栄化学工業株式会社 | Method for producing plant extract and cosmetics |
| FR2939799B1 (en) | 2008-12-11 | 2011-03-11 | Sederma Sa | COSMETIC COMPOSITION COMPRISING ACETYL OLIGOGLUCURONANS. |
| WO2010082177A2 (en) | 2009-01-16 | 2010-07-22 | Sederma | New compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses |
| FR2941231B1 (en) | 2009-01-16 | 2016-04-01 | Sederma Sa | NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES |
| FR2941232B1 (en) | 2009-01-16 | 2014-08-08 | Sederma Sa | NOVEL PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES |
| FR2944435B1 (en) | 2009-04-17 | 2011-05-27 | Sederma Sa | COSMETIC COMPOSITION COMPRISING ORIDONIN |
| FR2945939B1 (en) | 2009-05-26 | 2011-07-15 | Sederma Sa | COSMETIC USE OF TYR-ARG DIPEPTIDE TO FIGHT SKIN RELEASE. |
| JP2014208596A (en) * | 2013-04-16 | 2014-11-06 | 一丸ファルコス株式会社 | Cosmetics for making horny layer transparent |
| JP6025684B2 (en) * | 2013-09-25 | 2016-11-16 | 一丸ファルコス株式会社 | Caspase-14 expression inducer by phenylethylamine derivative or synephrine |
| WO2015194054A1 (en) * | 2014-06-20 | 2015-12-23 | 一丸ファルコス株式会社 | Inducer for expression of desmoplakin or inducer for localization of desmoplakin in cell membrane, which contains phenylethylamine derivative or synephrine |
| JP6401838B1 (en) * | 2017-08-18 | 2018-10-10 | メディカランド株式会社 | Whitening cosmetic composition |
| FR3143341A1 (en) * | 2022-12-14 | 2024-06-21 | L'oreal | Use of one or more particular alkylamine compounds for the cosmetic treatment of keratin fibers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5147778B2 (en) * | 1973-12-01 | 1976-12-16 | ||
| US4609544A (en) * | 1983-07-05 | 1986-09-02 | Repligen Corporation | Process for tanning the skin |
| US4515773A (en) * | 1983-07-05 | 1985-05-07 | Repligen Corporation | Skin tanning composition and method |
| US5879690A (en) * | 1995-09-07 | 1999-03-09 | Perricone; Nicholas V. | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
| US6162419A (en) * | 1996-11-26 | 2000-12-19 | Nicholas V. Perricone | Stabilized ascorbyl compositions |
| US5939458A (en) * | 1997-09-22 | 1999-08-17 | Henry; James P. | Reduction of hair growth |
| DE19860754B4 (en) * | 1998-06-24 | 2004-10-28 | Coty B.V. | Cosmetic preparation |
| DE19858670C2 (en) * | 1998-12-18 | 2001-07-12 | Heinz Kasik | Means for the care of skin, nails and hair and for the promotion of hair growth |
-
2000
- 2000-08-25 FR FR0011002A patent/FR2813188B1/en not_active Expired - Lifetime
-
2001
- 2001-08-10 WO PCT/FR2001/002597 patent/WO2002015871A1/en active Application Filing
- 2001-08-10 AU AU2001284135A patent/AU2001284135A1/en not_active Abandoned
- 2001-08-10 JP JP2002520780A patent/JP4393064B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004506677A (en) | 2004-03-04 |
| FR2813188A1 (en) | 2002-03-01 |
| FR2813188B1 (en) | 2003-01-17 |
| WO2002015871A1 (en) | 2002-02-28 |
| AU2001284135A1 (en) | 2002-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4393064B2 (en) | How to use tyramine as a cosmetic ingredient to make white skin | |
| JP4594091B2 (en) | Cosmetic or dermatological composition | |
| JP6553845B2 (en) | Skin / hair lightening composition | |
| TWI407976B (en) | Pigmentation-regulating compounds | |
| JP5686365B2 (en) | Collagen production promoter, photoaging inhibitor, moisturizing function improving agent and dermatological composition | |
| FR2854897A1 (en) | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS FOR REDUCING THE SIGNS OF SKIN AGING. | |
| JP6387219B2 (en) | Skin external preparation composition containing tangeretin and EGCG | |
| JP2005504755A (en) | Cosmetic and / or pharmaceutical preparations containing plant extracts | |
| CA2716667A1 (en) | Compositions comprising a skin-lightening resorcinol and a skin darkening agent | |
| KR20090084624A (en) | Methods of treating skin with aromatic skin-active ingredients | |
| CN112752566A (en) | Plant extracts and bacterial extracts exhibiting retinoid activity | |
| CN113616680A (en) | Nannochloropsis sp extract and application thereof | |
| JP2003524650A (en) | Cosmetic preparation containing plant extract | |
| FR2826579A1 (en) | COSMETIC COMPOSITION CONTAINING AT LEAST ONE OIL EXTRACTED FROM CUCURBITACEOUS SEEDS, ITS COSMETIC, THERAPEUTIC AND FOOD USE | |
| FR2973230A1 (en) | USE OF GINGERONE OR ITS DERIVATIVES TO DECREASE OR DELAY THE SIGNS OF SKIN AGING | |
| FR3018190A1 (en) | LIGHTENING COSMETIC COMPOSITION | |
| KR101921043B1 (en) | Compositions comprising lilium martagon extracts and uses thereof | |
| KR101921044B1 (en) | Compositions comprising lilium martagon extracts and uses thereof | |
| CN1507852A (en) | Use of ascorbic-acid dervative as bleaching agent for beauty | |
| FR3033699A1 (en) | EXTRACT OF CHINA PEPPER, COMPOSITION COMPRISING SAID EXTRACT AND COSMETIC USE | |
| JP2005509659A (en) | Anti-aging agent | |
| JP2005509659A6 (en) | Anti-aging agent | |
| FR2818149A1 (en) | COMPOSITION, ESPECIALLY COSMETIC, COMPRISING 7-HYDROXY DHEA AND / OR 7-CETO DHEA AND AT LEAST ONE 5 ALPHA-REDUCTASE INHIBITOR | |
| EP2590622B1 (en) | Use of populus balsamifera extract as depigmenting agent | |
| KR100364314B1 (en) | Use of unfermented honey as a depigmenting agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050421 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060413 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060913 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061106 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061225 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070502 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081016 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090710 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091013 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4393064 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121023 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121023 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131023 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |